Observational analysis found that higher CDAI is linked to improved CKM staging and lower mortality rates in adult populations, indicating dietary antioxidant benefits.
Abstract This study investigated the role of the Composite Dietary Antioxidant Index (CDAI) in cardiovascular-kidney-metabolic (CKM) syndrome staging and mortality using NHANES 2001–2018 data from 25,155 U.S. adults. Higher CDAI quartiles demonstrated progressively reduced odds of advanced CKM stages versus Stage 0 (Q4 vs. Q1 ORs: Stage 1: 0.71 (0.56–0.91); Stage 2: 0.58 (0.45–0.74); Stage 3: 0.30 (0.20–0.47); Stage 4: 0.46 (0.35–0.60); all P < 0.05). Weighted Quantile Sum regression identified a protective effect of the antioxidant mixture against advanced CKM (OR: 0.82 (0.76–0.88); P < 0.001), primarily driven by vitamins A (weight = 0.357), C (0.290), and selenium (0.212). In CKM patients, higher CDAI was associated with significantly lower all-cause (Q4 vs. Q1 HR: 0.63 (0.57–0.70)), cardiovascular (HR: 0.63 (0.51–0.78)), and non-cardiovascular mortality (HR: 0.63 (0.56–0.72); all P < 0.001). Nonlinear analyses revealed threshold effects for all-cause and non-CVD mortality at CDAI ≈ 0. These findings indicate that elevated CDAI is robustly associated with less severe CKM staging and reduced mortality, supporting dietary antioxidant optimization for CKM management and risk stratification.
No takes yet. Share an insight, caveat, or question.
wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: